Shukra Pharmaceuticals Q1 Results: Net Profit Rises 13.6x YoY to ₹1,502.98 Lakh

Shukra Pharmaceuticals reported a substantial turnaround in profitability for the first quarter of FY26, with standalone net profit rising to ₹1,502.98 lakh compared to ₹102.96 lakh in the corresponding period of FY25. The surge was underpinned by a 336% year-on-year increase in revenue from operations, which reached ₹2,352.23 lakh against ₹539.11 lakh in Q1FY25. This performance marks a sharp recovery from the net loss of ₹172.67 lakh reported in the preceding quarter (Q4FY25), signaling improved operational efficiency and demand for its pharmaceutical products.

The Board of Directors approved the unaudited financial results at a meeting held on August 12, 2026, at the company’s registered office in Ahmedabad. The results were reviewed by the Audit Committee and subjected to a limited review by M/s Shah Sanghvi and Associates, Chartered Accountants, the statutory auditors of the company. The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) 34 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

Metric	Q1FY26 (₹ Lakh)	Q4FY25 (₹ Lakh)	Q1FY25 (₹ Lakh)
Revenue from Operations	2,352.23	630.29	539.11
Net Profit / (Loss)	1,502.98	(172.67)	102.96
Earnings Per Share (Basic)	₹0.34	(₹0.04)	₹0.02
Total Expenses	381.97	688.25	512.78

Consolidated net profit for the quarter stood at ₹1,295.85 lakh, compared to ₹102.96 lakh in Q1FY25. Consolidated revenue from operations remained consistent with standalone figures at ₹2,352.23 lakh. The consolidated segment information reveals that the pharmaceutical segment generated a pre-tax and pre-interest profit of ₹1,860.13 lakh, while the MedTech segment, effective from October 1, 2025, contributed no revenue or profit in this period.

What the Numbers Show

The most striking aspect of the Q1FY26 results is the dramatic improvement in operating leverage. While revenue surged by over three times compared to the prior year, total expenses decreased significantly to ₹381.97 lakh from ₹512.78 lakh in Q1FY25. This divergence suggests a major shift in cost structure or inventory management, evidenced by a change in inventory valuation of (₹279.00 lakh) versus a positive ₹201.88 lakh in the previous year. Additionally, finance costs increased modestly to ₹42.95 lakh from ₹26.81 lakh, but this was more than offset by the expansion in top-line growth, resulting in a profit before tax of ₹2,024.23 lakh, up from ₹137.30 lakh in Q1FY25.

The company operates in two segments: Shukra Pharmaceutical and Shukra MedTech. The pharmaceutical segment remains the primary driver of value, accounting for all reported revenue and the majority of segment assets. No investor complaints were received during the quarter ended June 30, 2026, indicating stable stakeholder relations. The paid-up equity share capital remained unchanged at ₹4,378.79 lakh.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+6.87%	+32.34%	+17.50%	-10.44%	+116.88%	+9,612.20%

Shukra Pharmaceuticals Limited approved the preferential issue of 46,43,000 convertible equity warrants to promoters for cash consideration during its Extra Ordinary General Meeting (EOGM) held on July 06, 2026. The approval was secured via a special resolution under Regulation 170(2) of the SEBI (ICDR) Regulations, 2018, enabling the company to raise capital from its promoters.

The meeting was conducted through video conferencing and other audio-visual means in compliance with the Companies Act, 2013, and relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI). Mr. Dakshesh Shah, Managing Director, chaired the meeting, which commenced at 12:00 p.m. and concluded at 12:25 p.m. (IST).

Voting and Proceedings

The requisite quorum was present for the meeting. The company appointed Mrs. Rupal Patel, a Practicing Company Secretary, as the Scrutinizer to oversee the remote e-voting process and the e-voting conducted during the EOGM. Remote e-voting was open from July 03, 2026, at 09:00 a.m. to July 05, 2026, at 05:00 p.m., facilitated by Purva Sharegistry (India) Private Limited.

Resolution Details

The sole item on the agenda was the special business regarding the preferential allotment. The details of the resolution passed are as follows:

S.N.	Particulars	Type of Resolution
1	Approval under Regulation 170(2) of the SEBI (ICDR) Regulations, 2018 for Preferential Issue of 46,43,000 Convertible Equity Warrants to Promoters for cash consideration	Special Resolution

No queries were raised by the shareholders during the meeting. The results of the voting will be announced within 48 hours of the conclusion of the meeting and will be displayed on the company's website and the stock exchanges.